- CONSORT Statement
- CONSORT Statement Extensions
- Evidence underpinning CONSORT
- Accrual and sample size
- Attitudes to trials
- Adverse events (Harms)
- Baseline data
- Blinding
- Compliance
- Early stopping
- Eligibility
- Follow-up
- Funding
- Generalizability
- Harms
- Intention to treat
- Interpretation
- Interventions
- Outcome reporting
- Random allocation
- Recruitment
- Statistical analysis
- Statistical methods
- Trial design issues
- Trial registration
- Uptake of CONSORT by journals
- Impact of and adherence to CONSORT
- Endorsement of CONSORT
Statistical analysis
Adams KF, Jr. Post hoc subgroup analysis
and the truth of a clinical trial. Am Heart J 1998; 136(5):753-758.
PMID: 9812066
Altman DG, Andersen PK. Calculating the number needed to
treat for trials where the outcome is time to an event. BMJ 1999;
319(7223):1492-1495.
PMID: 10582940
Altman DG. Confidence intervals for the number needed to
treat. BMJ 1998; 317(7168):1309-1312.
PMID: 9804726
Amit O, Heiberger RM, Lane PW. Graphical approaches to the analysis of safety data from clinical trials. Pharm Stat 2008; 7(1):20-35.
PMID: 17323410
Bailar JC, III, Mosteller F. Guidelines for statistical
reporting in articles for medical journals. Amplifications and explanations.
Ann Intern Med 1988; 108(2):266-273.
PMID: 3341656
Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schunemann HJ, Tornetta P, III.
Misuse of baseline comparison tests and subgroup analyses in surgical trials.
Clin Orthop Relat Res 2006; 447:247-251.
PMID: 16672904 [New]
Bland JM. Quoting intermediate analyses can only mislead.
BMJ 1997; 314(7098):1907-1908.
PMID: 9224157
Cook RJ, Sackett DL. The number needed to treat: a
clinically useful measure of treatment effect. BMJ 1995; 310(6977):452-454.
PMID: 7873954
Dongsheng T, Shalay K, Pater J. Adjustment of treatment
effects for covariates in clinical trials: statistical and regulatory issues.
Drug Information Journal 2000; 34:511-523. Duncan BW, Olkin I. Bias of
estimates of the number needed to treat. Stat Med 2005; 24(12):1837-1848.
PMID: 15806616
Feise RJ. Do multiple outcome measures require p-value
adjustment? BMC Med Res Methodol 2002; 2:8.
PMID: 12069695
Gardner MJ, Altman DG. Confidence intervals rather than P
values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986;
292(6522):746-750.
PMID: 3082422
Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ,
Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ,
Sydes MR, Walker AE, Wallace SA. Issues in data monitoring and interim analysis
of trials. Health Technol Assess 2005; 9(7):1-iv.
PMID: 15763038
Hernandez AV, Boersma E, Murray GD, Habbema JD, Steyerberg
EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most
of them misleading? Am Heart J 2006; 151(2):257-264.
PMID: 16442886
Julien M, Hanley JA. Profile-specific survival estimates: Making reports of clinical trials more patient-relevant. Clin Trials 2008; 5(2):107-115.
PMID: 18375648 [New]
Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008; 26(22):3721-3726.
PMID: 18669458 [New]
Moreira ED, Jr., Stein Z, Susser E. Reporting on methods of
subgroup analysis in clinical trials: a survey of four scientific journals.
Braz J Med Biol Res 2001; 34(11):1441-1446.
PMID: 11668354
Murray DM, Pals SL, Blitstein JL, Alfano CM, Lehman J. Design and analysis of group-randomized trials in cancer: a review of current practices. J Natl Cancer Inst 2008; 100(7):483-491.
PMID: 18364501 [New]
Newcombe RG. Confidence intervals for the number needed to
treat. Absolute risk reduction is less likely to be misunderstood. BMJ 1999;
318(7200):1765-1767.
PMID: 10428570
Nuovo J, Melnikow J, Chang D. Reporting number needed to
treat and absolute risk reduction in randomized controlled trials. JAMA 2002;
287(21):2813-2814.
PMID: 12038920
Pocock SJ, Hughes MD. Estimation issues in clinical trials
and overviews. Stat Med 1990; 9(6):657-671.
PMID: 2145623
Pocock SJ, Travison TG, Wruck LM. Figures in clinical trial
reports: current practice and scope for improvement. Trials 2007; 8(1):36.
PMID: 18021449
Pocock SJ, Collier TJ, Dandreo
KJ, de Stavola BL, Goldman MB, Kalish LA, Kasten LE, McCormack VA. Issues in the reporting of epidemiological studies: a survey of
recent practice. BMJ 2004; 329(7471):883.
PMID: 15469946
Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the
reporting of clinical trials. A survey of three medical journals. N Engl J Med
1987; 317(7):426-432.
PMID: 3614286
Rothwell PM. Treating individuals 2. Subgroup analysis in
randomised controlled trials: importance, indications, and interpretation.
Lancet 2005; 365(9454):176-186.
PMID: 15639301
Schulz KF, Grimes DA. Multiplicity in randomised trials II:
subgroup and interim analyses. Lancet 2005; 365(9471):1657-1661.
PMID: 15885299
Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio
measures in leading medical journals: structured review of accessibility of
underlying absolute risks. BMJ 2006; 333(7581):1248.
PMID: 17060338
Tukey JW. Some thoughts on clinical trials, especially
problems of multiplicity. Science 1977; 198(4318):679-684.
PMID: 333584
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM.
Statistics in medicine--reporting of subgroup analyses in clinical trials. N
Engl J Med 2007; 357(21):2189-2194.
PMID: 18032770
Wedel H, Demets D, Deedwania P, Fagerberg B, Goldstein S,
Gottlieb S, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J. Challenges of
subgroup analyses in multinational clinical trials: experiences from the
MERIT-HF trial. Am Heart J 2001; 142(3):502-511.
PMID: 11526365
Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and
interpretation of treatment effects in subgroups of patients in randomized
clinical trials. JAMA 1991; 266(1):93-98.
PMID: 2046134
Page last edited: 23 March 2010
